Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Meghan C. Thompson · SciRah

Researcher profile · Semantic Scholar

Meghan C. Thompson

Share profile

Meghan C. Thompson — researcher profile on SciRah

h-index: 21
Works: 89
Citations: 2,089

Most-cited papers

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
A. Mato, C. Nabhan, Meghan C. Thompson, N. Lamanna +22 more
2018Haematologica422 citations Open access
Semantic Scholar
Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors
E. Wang, Xiaoli Mi, Meghan C. Thompson, S. Montoya +31 more
2022New England Journal of Medicine199 citations Open access
Semantic Scholar
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
A. Mato, Meghan C. Thompson, J. Allan, D. Brander +44 more
2018Haematologica155 citations Open access
Semantic Scholar
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
S. Montoya, J. Bourcier, M. Noviski, Hao Lu +49 more
2024Science141 citations Open access
Semantic Scholar
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia
L. Roeker, D. Knorr, Meghan C. Thompson, Mariely Nivar +14 more
2021Leukemia128 citations Open access
Semantic Scholar
Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia
L. Roeker, D. Knorr, M. Pessin, L. Ramanathan +4 more
2020Leukemia93 citations Open access
Semantic Scholar
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial
J. Soumerai, A. Mato, A. Dogan, V. Seshan +42 more
2021The Lancet Haematology85 citations Open access
Semantic Scholar
First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)
J. Seymour, C. Cheah, Ricardo D. Parrondo, Meghan C. Thompson +14 more
2023Blood63 citations Open access
Semantic Scholar
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
L. Roeker, T. Eyre, Meghan C. Thompson, N. Lamanna +48 more
2021Blood62 citations Open access
Semantic Scholar
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024.
W. Wierda, Jennifer R. Brown, J. S. Abramson, Farrukh T. Awan +32 more
2024The Journal of the National Comprehensive Cancer Network60 citations Open access
Semantic Scholar
A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies
Alexey V. Danilov, M. Tees, K. Patel, W. Wierda +16 more
2023Blood55 citations Open access
Semantic Scholar
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
Meghan C. Thompson, R. Harrup, Catherine C. Coombs, L. Roeker +34 more
2022Blood Advances53 citations Open access
Semantic Scholar
New Directions for Mantle Cell Lymphoma in 2022.
Anita Kumar, T. Eyre, K. Lewis, Meghan C. Thompson +1 more
2022American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting49 citations
Semantic Scholar
Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review
Meghan C. Thompson, D. Brander, C. Nabhan, A. Mato
2017JAMA Oncology38 citations
Semantic Scholar
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study
Meghan C. Thompson, Ricardo D. Parrondo, A. Frustaci, J. Allan +13 more
2024Blood34 citations
Semantic Scholar
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
M. Stanchina, S. Montoya, Alexey V. Danilov, J. Castillo +9 more
2024Nature Reviews Clinical Oncology32 citations
Semantic Scholar
Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1
Alexey V. Danilov, B. Fakhri, Farrukh T. Awan, H. Bentzen +19 more
2024Blood30 citations
Semantic Scholar
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial
N. Shah, Michael Wang, L. Roeker, Krish Patel +31 more
2024Haematologica25 citations Open access
Semantic Scholar
Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia
S. Montoya, Meghan C. Thompson
2023Cancers25 citations Open access
Semantic Scholar
Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL
J. Soumerai, J. C. Barrientos, Inhye E. Ahn, Catherine C. Coombs +14 more
2024Blood Advances23 citations Open access
Semantic Scholar
Approach to a patient with “double refractory” chronic lymphocytic leukemia: “Double, double toil and trouble” (Shakespeare)
Julia H. Aronson, S. Skånland, L. Roeker, Meghan C. Thompson +1 more
2022American journal of hematology/oncology21 citations Open access
Semantic Scholar
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What’s Past is Prologue” (Shakespeare)
A. Mato, M. Davids, J. Sharman, L. Roeker +24 more
2021Clinical Cancer Research19 citations Open access
Semantic Scholar
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL
A. Kittai, Ying Huang, Sarah Miller, John N. Allan +41 more
2025Blood Cancer Journal17 citations Open access
Semantic Scholar
Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax
Meghan C. Thompson, L. Roeker, Catherine C. Coombs, J. L. Jensen +26 more
2021Blood17 citations Open access
Semantic Scholar
Venetoclax Re-Treatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based Regimen
Meghan C. Thompson, J. Allan, K. Sail, B. Manzoor +22 more
202014 citations Open access
Semantic Scholar
Chimeric Antigen Receptor T‐Cell Therapy for Chronic Lymphocytic Leukemia: A Narrative Review
A. Mato, Meghan C. Thompson, C. Nabhan, J. Svoboda +1 more
2017Clinical Lymphoma, Myeloma & Leukemia14 citations
Semantic Scholar
Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)
J. Soumerai, A. Doğan, V. Seshan, K. Flaherty +52 more
2024Blood13 citations
Semantic Scholar
PIRTOBRUTINIB (LOXO‐305), A NEXT GENERATION HIGHLY SELECTIVE NON‐COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED RICHTER TRANSFORMATION: RESULTS FROM THE PHASE 1/2 BRUIN STUDY
W. Jurczak, N. Shah, N. Lamanna, T. Eyre +14 more
2021Hematological Oncology13 citations Open access
Semantic Scholar
A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma
A. Mato, S. Schuster, F. Foss, I. Isufi +20 more
202013 citations Open access
Semantic Scholar
Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders
S. Montoya, J. Bourcier, Meghan C. Thompson, M. Noviski +28 more
2022Blood12 citations Open access
Semantic Scholar
Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial.
A. Kater, A. Janssens, Herbert A. Eradat, F. Offner +13 more
2025The Lancet Haematology11 citations Open access
Semantic Scholar
Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure
Kuo-Kai Chin, B. Ball, Yasmin M. Abaza, Jessica K. Altman +13 more
2025Blood Advances11 citations Open access
Semantic Scholar
Real-world incidence and prevention of tumor lysis syndrome in chronic lymphocytic leukemia treated with venetoclax
Yannis K. Valtis, D. Nemirovsky, A. Derkach, Saumya Sharan +5 more
2024Blood Advances11 citations Open access
Semantic Scholar
Universal germline genetic testing in patients with hematologic malignancies using DNA isolated from nail clippings
O. Ceyhan-Birsoy, Elise M. Fiala, Satshil Rana, M. Sheehan +41 more
2024Haematologica11 citations Open access
Semantic Scholar
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase 2 Study of an MRD-driven Approach
L. Roeker, T. Feldman, J. Soumerai, V. Falco +22 more
2022Clinical Cancer Research11 citations Open access
Semantic Scholar
Treatment of relapsed chronic lymphocytic leukemia after venetoclax.
Meghan C. Thompson, A. Mato
2020Hematology. American Society of Hematology. Education Program10 citations Open access
Semantic Scholar
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026.
W. Wierda, Jennifer R. Brown, Jeremy S. Abramson, Farrukh T. Awan +33 more
2026The Journal of the National Comprehensive Cancer Network8 citations
Semantic Scholar
Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study
Inhye E. Ahn, Ricardo D. Parrondo, Meghan C. Thompson, A. Frustaci +16 more
2025Blood8 citations
Semantic Scholar
Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
Meghan C. Thompson, A. Mato
2021Hematology/Oncology Clinics of North America8 citations
Semantic Scholar
Current Treatment of Chronic Lymphocytic Leukemia: the Diminishing Role of Chemoimmunotherapy
L. Roeker, Meghan C. Thompson, A. Mato
2021Drugs8 citations Open access
Semantic Scholar
Ruxolitinib Promotes Clinical Responses in Large Granular Lymphocytic Leukemia Via Suppression of JAK/STAT-Dependent Inflammatory Cascades
A. Moskowitz, Jahan Rahman, N. Ganesan, Kelly Hannigan +19 more
2023Blood7 citations Open access
Semantic Scholar
A First-in-Human Phase 1 Study of ABBV-525, a Small-Molecule MALT1 Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Andrew Sochacki, J. Burger, C. Ludwig, Wissam Assaily +5 more
2023Blood6 citations Open access
Semantic Scholar
Outcomes of Patients with Richter Transformation without Prior Chemoimmunotherapy for CLL/SLL: An International Multicenter Retrospective Study
A. Kittai, Ying Huang, Sarah Miller, J. Allan +41 more
2023Blood6 citations Open access
Semantic Scholar
Worldwide Examination of Patients with CLL Hospitalized for COVID-19
L. Roeker, L. Scarfò, T. Chatzikonstantinou, P. Abrisqueta +149 more
2020Blood6 citations Open access
Semantic Scholar
Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study
Meghan C. Thompson, S. Bhat, W. Jurczak, K. Patel +18 more
2024Blood5 citations
Semantic Scholar
A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach
L. Roeker, L. Leslie, J. Soumerai, V. Falco +17 more
2021Blood5 citations Open access
Semantic Scholar
A Phase 2 Study of Minimal Residual Disease (MRD)-Adapted Front Line Venetoclax and Obinutuzumab in Fit Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Obinutuzumab on Tumor Lysis Syndrome (TLS) Risk and Safety of Outpatient Venetoclax Dose Escalation
L. Roeker, A. Zelenetz, Jae H. Park, A. Derkach +22 more
2023Blood4 citations Open access
Semantic Scholar
Chemotherapy-Sparing Induction Followed By Consolidation and Maintenance with Blinatumomab and Concurrent Oral Tyrosine Kinase Inhibitor Therapy for Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Primary Endpoint Results from the Blissphall Study
M. Geyer, J. Mascarenhas, Marissa Smith, S. Pascual +6 more
2023Blood4 citations Open access
Semantic Scholar
Molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation
Quinlan Sievers, Hao Lu, Allison Cool, Stefan Gajewski +23 more
2025Blood3 citations
Semantic Scholar
Management of Relapsed and/or Refractory Chronic Lymphocytic Leukemia
A. Kagerer, Meghan C. Thompson
2025Hematology/Oncology Clinics of North America3 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Mato×25
Invite
A. Mato — researcher profile on SciRah
L. Roeker×25
Invite
L. Roeker — researcher profile on SciRah
A. Zelenetz×14
Invite
A. Zelenetz — researcher profile on SciRah
S. Schuster×9
Invite
S. Schuster — researcher profile on SciRah

×9

Invite

C. Ujjani — researcher profile on SciRah

Invite

T. Eyre — researcher profile on SciRah

Invite

D. Brander — researcher profile on SciRah

Invite

A. Skarbnik — researcher profile on SciRah

Catherine C. Coombs×8

Invite

Catherine C. Coombs — researcher profile on SciRah

Invite

J. Allan — researcher profile on SciRah

Invite

J. Woyach — researcher profile on SciRah

Invite

N. Lamanna — researcher profile on SciRah